You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 6,770,304


✉ Email this page to a colleague

« Back to Dashboard


Title: Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Abstract:The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Inventor(s): Warrell, Jr.; Raymond P. (Westfield, NJ), Pandolfi; Pier Paolo (New York, NY), Gabrilove; Janice L. (New York, NY)
Assignee: Memorial Sloan-Kettering Cancer Center (New York, NY)
Filing Date:Nov 10, 1998
Application Number:09/189,965
Claims:1. A method of treating acute myelogenous leukemia in a human comprising administering to a human having acute myelogenous leukemia a therapeutically effective amount of arsenic trioxide, wherein the acute myelogenous leukemia is selected from the group consisting of acute myeloblastic leukemia, acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, or acute undifferentiated leukemia.

2. A method for treating chronic myelogenous leukemia in a human comprising administering to a human with chronic myelogenous leukemia a therapeutically effective amount of arsenic trioxide.

3. A method for treating acute myelogenous leukemia or chronic myelogenous leukemia in a human who is resistant to treatment with retinoids comprising administering to the human a therapeutically effective amount of arsenic trioxide, wherein the acute myelogenous leukemia is selected from the group consisting of acute myeloblastic leukemia, acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, or acute undifferentiated leukemia.

4. The method of claim 1, 2, or 3, wherein arsenic trioxide is administered by intravenous infusion.

5. The method of claim 4 wherein about 1 to 40 mg of arsenic trioxide is administered per day.

6. The method of claim 1, 2, or 3, wherein administration of arsenic trioxide is repeated daily until bone marrow remission is observed in the human.

7. The method of claim 1, 2, or 3, wherein all-trans retinoic acid is also administered to the human.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.